Next Article in Journal
Stress and the HPA Axis: Balancing Homeostasis and Fertility
Previous Article in Journal
Coumestrol Epigenetically Suppresses Cancer Cell Proliferation: Coumestrol Is a Natural Haspin Kinase Inhibitor
Previous Article in Special Issue
Non-Coding RNAs as Predictive Biomarkers to Current Treatment in Metastatic Colorectal Cancer
Article Menu
Issue 10 (October) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2017, 18(10), 2229; https://doi.org/10.3390/ijms18102229

Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications

1
Tumor Biology, Immunology, and Therapy Section, Immunology, Inflammation, and Metabolism Department, Division of Translational Medicine, Sidra Medical and Research Center, PO Box 26999 Doha, Qatar
2
Department of Surgery, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
3
Academic Medical Center Amsterdam, Center for Experimental Molecular Medicine, 1105AZ Amsterdam, The Netherlands
4
Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Qatar Foundation, PO Box 5825 Doha, Qatar
5
Office of the Chief Research Officer (CRO), Sidra Medical and Research Center, PO Box 26999 Doha, Qatar
Current employer: Abbvie Biotherapeutics Corporation, 94063 Redwood City, CA, USA
These authors contributed equally to this work.
*
Authors to whom correspondence should be addressed.
Received: 11 September 2017 / Revised: 6 October 2017 / Accepted: 20 October 2017 / Published: 24 October 2017
View Full-Text   |   Download PDF [2440 KB, uploaded 25 October 2017]   |  

Abstract

The immune system has a substantial effect on colorectal cancer (CRC) progression. Additionally, the response to immunotherapeutics and conventional treatment options (e.g., chemotherapy, radiotherapy and targeted therapies) is influenced by the immune system. The molecular characterization of colorectal cancer (CRC) has led to the identification of favorable and unfavorable immunological attributes linked to clinical outcome. With the definition of consensus molecular subtypes (CMSs) based on transcriptomic profiles, multiple characteristics have been proposed to be responsible for the development of the tumor immune microenvironment and corresponding mechanisms of immune escape. In this review, a detailed description of proposed immune phenotypes as well as their interaction with different therapeutic modalities will be provided. Finally, possible strategies to shift the CRC immune phenotype towards a reactive, anti-tumor orientation are proposed per CMS. View Full-Text
Keywords: colorectal cancer; tumor microenvironment; immune contexture; immunologic constant of rejection; consensus molecular subtypes; immunotherapy; combination therapy colorectal cancer; tumor microenvironment; immune contexture; immunologic constant of rejection; consensus molecular subtypes; immunotherapy; combination therapy
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Roelands, J.; Kuppen, P.J.K.; Vermeulen, L.; Maccalli, C.; Decock, J.; Wang, E.; Marincola, F.M.; Bedognetti, D.; Hendrickx, W. Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications. Int. J. Mol. Sci. 2017, 18, 2229.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top